كندا - الإنجليزية - Health Canada

teva canada limited - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg - monoamine oxidase b inhibitors

كندا - الإنجليزية - Health Canada

teva canada limited - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg - monoamine oxidase b inhibitors

كندا - الإنجليزية - Health Canada

mint pharmaceuticals inc - rasagiline (rasagiline mesylate) - tablet - 0.5mg - rasagiline (rasagiline mesylate) 0.5mg

كندا - الإنجليزية - Health Canada

mint pharmaceuticals inc - rasagiline (rasagiline mesylate) - tablet - 1mg - rasagiline (rasagiline mesylate) 1mg

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - rasagiline - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - rasagiline - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - rasagiline tartrate - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - rasagiline - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - rasagiline tartrate - tablet - 1 milligram(s) - monoamine oxidase b inhibitors; rasagiline

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

indoco remedies limited - rasagiline mesylate (unii: lh8c2ji290) (rasagiline - unii:003n66ts6t) - rasagiline tablets are indicated for the treatment of parkinson’s disease (pd). rasagiline tablets are contraindicated for use with meperidine, tramadol, methadone, propoxyphene and mao inhibitors (maois), including other selective mao-b inhibitors, because of risk of serotonin syndrome [see warnings and precautions (5.2)]. at least 14 days should elapse between discontinuation of rasagiline tablets and initiation of treatment with these medications. rasagiline tablets are contraindicated for use with st. john’s wort and with cyclobenzaprine. rasagiline tablets are contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. risk summary there are no adequate data on the development risk associate with the use of rasagiline in pregnant women. in animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses similar to those used clinically.